Wanbury Enters Paediatric Dermatology Segment with berrysoft Baby Product Launch
Wanbury Ltd 路 Press Release 路 12 Oct 2026, 6:58 pm
Wanbury Enters Paediatric Dermatology Segment with berrysoft Baby Product Launch Wanbury Limited's subsidiary, Wanbury Skin Health Limited, launched its berrysoft baby skincare range across multiple Indian states, marking its strategic entry into paediatric dermatology. The subsidiary secured GST registrations in five states, including Maharashtra, Delhi, and Karnataka, with three more pending, alongside CFA Drug Licenses across Mumbai, Jaipur, Patna, and Ambala, with four in pipeline. The initial rollout includes bathing bars, body wash, shampoo, and handwash, with lotions and diaper rash creams in pipeline, leveraging existing paediatrician networks to drive cross-selling growth.
Original exchange filing (PDF)
More announcements from Wanbury Ltd
- Clarifications on investor queries regarding recent announcement 路 16 Nov 2026
- Wanbury Limited''s Tanuku Plant - US FDA Inspection - Updates 路 16 Nov 2026
- Wanbury Limited received regulatory approval (CADIFA: Letter of suitability for API) from ANVISA (Brazil FDA) for its flagship product Metformin HC1 EP grade. 路 12 Nov 2026
- Press Release on Standalone and Consolidated Un-audited Financial Results for the second quarter & half year ended 30th September, 2026. 路 06 Nov 2026
- Financial Results as on 30th September, 2026 路 05 Nov 2026
- Outcome of the Board Meeting held on November 04, 2026 路 05 Nov 2026
- Wanbury Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 05 Nov 2026
- Wanbury Limited receives Australian TGA GMP Compliance Certificate for its Tanuku Plant, Strengthening Its Global Pharmaceutical Manufacturing Credentials. 路 30 Oct 2026
